Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Alnylam Pharmaceuticals, Inc. (ALNY) had Weighted-Average Shares Outstanding (Diluted) of 130.63M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$773.69M |
|
$-66.28M |
|
$142.95M |
|
$630.74M |
|
$789.89M |
|
$-16.20M |
|
$-19.16M |
|
$-35.36M |
|
$-35.36M |
|
$-66.28M |
|
$-66.28M |
|
$-66.28M |
|
$-66.28M |
|
$-16.20M |
|
$-2.25M |
|
130.63M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
130.63M |
$-0.51 |
|
$-0.51 |
|
| Balance Sheet Financials | |
$3.64B |
|
$499.79M |
|
$922.32M |
|
$4.57B |
|
$1.30B |
|
$1.03B |
|
$3.01B |
|
$4.32B |
|
$250.59M |
|
$250.59M |
|
$250.59M |
|
130.98M |
|
| Cash Flow Statement Financials | |
$35.42M |
|
$-27.61M |
|
$97.84M |
|
$968.65M |
|
$1.12B |
|
$147.21M |
|
$168.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.80 |
|
-- |
|
-- |
|
0.80 |
|
4.10 |
|
81.52% |
|
-2.09% |
|
-2.09% |
|
-- |
|
-4.57% |
|
-8.57% |
|
$12.15M |
|
-- |
|
-- |
|
-- |
|
0.17 |
|
1.99 |
|
1.36 |
|
65.97 |
|
-26.45% |
|
-26.45% |
|
-1.45% |
|
-5.19% |
|
$1.91 |
|
$0.09 |
|
$0.27 |
|